Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Next Previous
Trial Profile

Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SELECT
  • Sponsors Biogen Idec

Most Recent Events

  • 28 Apr 2017 Results examining degree of return of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) following discontinuation of treatment with daclizumab HYP (daclizumab) in SELECT/SELECTION Studies presented at the 69th Annual Meeting of the American Academy of Neurology
  • 09 Dec 2016 According to a Biogen media release, based on the results of this and other trial (DECIDE) Health Canada has approved ZINBRYTA™ (daclizumab beta), a new once-monthly, self-administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis (RRMS).
  • 05 Jul 2016 According to Biogen media release, the European Commission (EC) approved ZINBRYTA™ (daclizumab), for the treatment relapsing forms of multiple sclerosis (RMS) in adult patients. The European Commission (EC) approval was based upon this and DECIDE trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top